|
Prof Wyndham Wilson provides a comprehensive summary of the key lymphoma related research presented at the 2010 ASH congress in Florida. The first study discussed demonstrates that treating asymptomatic advanced stage follicular lymphoma patients with Rituxan (rituximab) rather than using the standard 'watch and wait' technique extends the time before the patient requires therapy. The second trial compared the Stanford V treatment regimen with ABVD treatment, which frequently involved radiotherapy, for patients with untreated advanced Hodgkin’s lymphoma. This study revealed that Stanford V was not superior to ABVD and clinicians must now decide if the shorter treatment time of Stanford V compensates for the additional toxicities associated with radiotherapy. The third study found that patients under 60 with diffuse large B-cell lymphoma had a significantly greater event free survival, progression free survival, disease free survival and overall survival than those treated with R-CHOP. Prof Wilson discusses the promising results of a study of the HDAC inhibitor romidepsin in peripheral T-cell lymphoma, a trial evaluating an anti-CCR4 monoclonal antibody known as KW-0761 in patients with adult T-cell lymphoma/leukaemia, a study looking to target CD30 protein cells with SGN-35 antibodies coupled to the cytotoxic monomethyl auristatin E in patients with Hodgkin's lymphoma and a study of dasatinib in relapsed or refractory non-Hodgkin's lymphoma.
|
Video Length: 0
Date Found: February 18, 2011
Date Produced:
|
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel discusses his research demonstrating the efficacy of bendamustine plus rituximab as a treatment for mantle cell lymphomas (MCL). Following the results presented at ASH 2009 revealing the superiority of bendamustine plus rituximab over CHOP plus rituximab as first line ...
|
www.ecancer.tv |
March 01, 2011
The panel discuss how the results of recent clinical trials have advanced our understanding of the optimal treatment for multiple myeloma. The development of new combinations containing drugs such as thalidomide, bortezomib and lenalidomide is helping clinicians achieve complete remission and ...
|
www.ecancer.tv |
March 01, 2011
Prof Mathias Rummel talks about the history of bendamustine from its origins in 1960’s East Germany to the modern trials evaluating the use of bendamustine and rituximab to treat lymphoproliferative diseases.
|
www.ecancer.tv |
March 01, 2011
Prof Antonio Palumbo and Prof Vincent Rajkumar discuss some of the key research into myeloma that was presented at ASH 2010. This includes trials demonstrating that post transplant lenalidomide maintenance treatment dramatically improves progression free survival, a study comparing bortezomib ...
|
www.ecancer.tv |
February 23, 2011
Prof Anton Hagenbeek discusses the five and a half year results of the First-Line Indolent Trial (FIT) study. The randomised phase III FIT study evaluates the clinical benefits and safety of a single infusion of Zevalin (ibritumomab tiuxetan) in patients with previously untreated follicular ...
|
|
|
|
|
|
Featured Content
Featuring websites that enhance the internet user’s experience.
|